Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13550263 | 0.91 | ADORA1 (0.41) | ADORA1SLC6A3RAB9A | |
| SCHEMBL3572722 | 0.91 | ADORA1 (0.50) | ADORA1SLC6A3 | |
| SCHEMBL14735654 | 0.89 | ADORA1 (0.37) | ADORA1SLC6A3PRNPRAB9A | |
| SCHEMBL3572737 | 0.89 | ADORA1 (0.51) | ADORA1SLC6A3 | |
| SCHEMBL13550056 | 0.83 | ADORA1 (0.49) | ADORA1SLC6A3 | |
| SCHEMBL3846615 | 0.79 | ADORA1 (0.62) | ADORA1SLC6A3 | |
| SCHEMBL3580448 | 0.79 | ADORA1 (0.62) | ADORA1SLC6A3 | |
| SCHEMBL3574634 | 0.76 | ADORA1 (0.49) | ADORA1SLC6A3RAB9A | |
| SCHEMBL3842754 | 0.76 | ADORA1 (0.40) | ADORA1FNTAFNTBSLC6A3PRNP | |
| SCHEMBL3575738 | 0.76 | ADORA1 (0.49) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099788-B1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER IP GMBH (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2099788-B1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER IP GMBH (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-8304412-B2 | Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304412-B2 | Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2099788-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008064788-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008064788-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | QDPR, TPMT, PTGIS | ADORA1 1717/4885FNTA 3590/4885FNTB 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.